"I am excited to join Atelerix Life Sciences as we work to bring this ground breaking new technology to clinical practice," said Dr. Bates. "Sudaxine promises to provide an entirely new approach to the tremendous problem of respiratory depression that accompanies the use of opioids and limits their therapeutic benefit."
Dr. Bates received his M.D. degree from the University of Miami in Miami, FL, and completed his residency in Anesthesiology at the University of Iowa in Iowa City. He received his BA and PhD in Biochemistry/Molecular Biology at the University of California Santa Barbara and completed a post-doctoral fellowship at the Salk Institute in San Diego.
About Atelerix Life Sciences Inc.
Atelerix Life Sciences Inc. is a preclinical biotech company developing a platform technology of new drugs targeting unmet medical needs arising from the opioid crisis. This novel drug family, including lead compound ATLX-0199 (also called Sudaxine), addresses death and morbidity from opioid-induced respiratory depression (OIRD) and other opioid-related conditions. The current approach to side effects from opioids is to administer opioid receptor antagonists such as naloxone, which can reverse these life-threatening conditions. These, however, carry significant risks and limitations, particularly as they suppress pain control, making them problematic in the surgical setting. Our solution, developed in collaboration with Stephen Lewis, PhD, Benjamin Gaston, MD, and James Bates, MD, PhD, is found within the new platform of small molecule drugs called Active Thiol-Based Compounds (ATBCs) targeted at safely preventing or reversing opioid-induced side effects via a novel molecular pathway. Sudaxine, Atelerix's lead drug candidate, is designed to reverse OIRD while preserving pain relief, with first uses targeted in the perioperative hospital setting.
David Gregory Kalergis
Atelerix Life Sciences
email us here
To read more People News articles, click here.